{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:37:55Z","timestamp":1782949075819,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,12]]},"DOI":"10.7759\/cureus.16337","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T13:55:12Z","timestamp":1626098112000},"source":"Crossref","is-referenced-by-count":13,"title":["Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Neha","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Peguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline. J Clin Oncol. 2018, 36:1714-68.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen YH","year":"2017","unstructured":"Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017, 96:e7350. 10.1097\/MD.0000000000007350","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen A","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D, H\u00f8jgaard JL, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology. 2019, 92:663-74. 10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management","volume":"39","author":"Kang KH","year":"2018","unstructured":"Kang KH, Grubb W, Sawlani K, et al.. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management. Am J Otolaryngol. 2018, 39:642-5. 10.1016\/j.amjoto.2018.06.003","journal-title":"Am J Otolaryngol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura T","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, et al.. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016, 107:1055-8. 10.1111\/cas.12961","journal-title":"Cancer Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao B","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014, 16:589-93. 10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12339","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24 Suppl 2","author":"Psimaras D","year":"2019","unstructured":"Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J, Argyriou AA. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019, 24 Suppl 2:S74-85. 10.1111\/jns.12339","journal-title":"J Peripher Nerv Syst"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn S","year":"2017","unstructured":"Supakornnumporn S, Katirji B. Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017, 19:80-3. 10.1097\/CND.0000000000000193","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.07.020","article-title":"Fatal acute motor axonal neuropathy induced by Nivolumab: a case report and literature review","volume":"17","author":"Yildirim N","year":"2019","unstructured":"Yildirim N, Gonen M, Balgetir F, Er MB. Fatal acute motor axonal neuropathy induced by Nivolumab: a case report and literature review. Clin Genitourin Cancer. 2019, 17:e1104-7. 10.1016\/j.clgc.2019.07.020","journal-title":"Clin Genitourin Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast N","year":"2010","unstructured":"Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010, 41:375-8. 10.1002\/mus.21521","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.125","article-title":"Rituximab in the treatment of pembrolizumab-induced myasthenia gravis","volume":"102","author":"Crusz SM","year":"2018","unstructured":"Crusz SM, Radunovic A, Shepherd S, et al.. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer. 2018, 102:49-51. 10.1016\/j.ejca.2018.07.125","journal-title":"Eur J Cancer"},{"key":"ref15","article-title":"The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects new drugs, indications, and combinations continue to emerge","volume":"41","author":"Alexander W","year":"2016","unstructured":"Alexander W. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects new drugs, indications, and combinations continue to emerge. P T. 2016, 41:185-191.","journal-title":"P T"},{"key":"ref16","unstructured":"Common terminology criteria for adverse events. (2018). Accessed. July 12, 2021: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan R","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017, 56:185-96. 10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13562","article-title":"Rituximab in myasthenia gravis: a \"to be or not to be\" inhibitor of T cell function","volume":"1413","author":"Marino M","year":"2018","unstructured":"Marino M, Bartoccioni E, Alboini PE, Evoli A. Rituximab in myasthenia gravis: a \"to be or not to be\" inhibitor of T cell function. Ann N Y Acad Sci. 2018, 1413:41-8. 10.1111\/nyas.13562","journal-title":"Ann N Y Acad Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54648-rituximab-for-immune-checkpoint-inhibitor-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:27:05Z","timestamp":1707488825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54648-rituximab-for-immune-checkpoint-inhibitor-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.16337","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-91621\/v1","asserted-by":"object"}]},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}